+91 97731 34699 [email protected]

Products Complies as per Regulatory requirements

PLGA is non-pharmacopeial Bioabsorbable polymer is widely

used for Drug delivery formulation as excipient in a

dosage forms.

Product List

 CAS number:26780-50-7
Systematic Name:

1, 4-Dioxane-2, 5-dione-1-DL-3, 6-dimethyl-1, 4-dioxane-2, 5-dione copolymer, Glycolide – lactide copolymer, Glycolide-DL-lactide copolymer, Glycolide-DL-lactide polymer, Lactide – glycolide copolymer, Lactomer, Poly(dl-lactide-co-glycolide), Poly(glycolide – lactide), Poly(glycolide-co-lactide), Polyglactin

Molecular Formula:

((C3H4O2)m x (C2H2O2)n

EPA Registry Name:

Polylactic acid-polyglycolic acid copolymer

Former CAS Number(s):

107760-14-5, 119652-89-0, 1255770-56-9, 130953-65-0, 31213-75-9, 339986-68-4

Substance Type:

 Biodegradable Polymer, Excipient, Non-Active pharmaceutical ingredient, Nanoparticles, Nanomedicine, Bio-absorbable polymer.

Synonym:

PLGA, Poly(D,L-lactide-co-glycolide) ,Poly(DL-lactide-co-glycolide), PGLA .

IdentificationPolymerRatio End GroupInherent Viscosity dl/gAsk for Details
DLG 50-2APLGA50/50COOH0.15-0.25 🧾
DLG 50-3APLGA50/50COOH0.25-0.40🧾
DLG 50-5APLGA50/50COOH0.40-0.55🧾
DLG 50-6APLGA50/50COOH0.55-0.65🧾
DLG 50-8APLGA50/50COOH0.55-0.65🧾
DLG 50-2EPLGA50/50ESTER0.15-0.25🧾
DLG 50-6EPLGA50/50ESTER0.55-0.65🧾
DLG 50-7EPLGA50/50ESTER0.60-0.70🧾
DLG 50-6PPLGA-PEG50/50PEG0.45-0.65🧾
DLG 50-7PPLGA-PEG50/50PEG0.65-0.80🧾
LG 50-7EPLGA50/50ESTER0.60-0.70🧾
LG 50-2EPLGA50/50ESTER0.15-0.25🧾
LG 50-7APLGA50/50COOH0.60-0.70🧾
LG 50-2APLGA50/50COOH0.15-0.25🧾
DLG 75-2APLGA75/25COOH0.08-0.21🧾
DLG 75-5APLGA75/25COOH0.38-0.64🧾
DLG 75-7APLGA75/25COOH0.60-0.70🧾
DLG 75-8APLGA75/25COOH0.70-0.90🧾
DLG 75-10APLGA75/25COOH0.80-1.10🧾
DLG 75-2EPLGA75/25ESTER0.15-0.30🧾
DLG 75-4EPLGA75/25ESTER0.30-0.50🧾
DLG 75-7EPLGA75/25ESTER0.66-0.80🧾
DLG 75-9EPLGA75/25ESTER0.75-1.00🧾
DLG 75-4APLGA75/25COOH0.30-0.50🧾
LG 75-2EPLGA75/25ESTER0.15-0.30🧾
LG 75-9EPLGA75/25ESTER0.75-1.00🧾
LG 75-2APLGA75/25COOH0.15-0.30🧾
LG 75-9APLGA75/25COOH0.75-1.00🧾
DLG 85-2APLGA85/15COOH0.15-0.25🧾
DLG 85-7APLGA85/15COOH0.55-0.75🧾
DLG 85-7EPLGA85/15ESTER0.55-0.75🧾
DLG 85-12EPLGA85/15ESTER1.00-1.30🧾
DLG 45-2APLGA45/55COOH0.15-0.30🧾
DLG 55-5APLGA55/45COOH0.40-0.50🧾
DLG 65-3APLGA65/35COOH0.25-0.35🧾
DLG 65-6APLGA65/35COOH0.50-0.65🧾
DLG 90-5APLGA90/10COOH0.35-0.55🧾
DLG 90-7APLGA90/10COOH0.60-0.75🧾
DLG 95-2APLGA95/5COOH0.15-0.25🧾
DLG 95-4APLGA95/5COOH0.25-0.50🧾
DLG 65-6EPLGA65/35ESTER0.50-0.65🧾
DLL 10-15EP(L/DL)LA10/90ESTER1.30-1.70🧾

 

The full name of PLA is Polylactic acid.

 

CAS Number: 26100-51-6

Other CAS Number: 33135-50-1

Systematic Name: Poly(2-hydroxy propionic acid)

Molecular Formula:((C3H4O2)m

EPA Registry Name: Polylactic acid

Substance Type: Biodegradable Polymer, Excipient, Non-Active pharmaceutical ingredient, Nanoparticles, Nanomedicine, Bio-absorbable polymer, Polymer for ACL Scrow.

Synonym: Polylactic acid, Poly(L-lactide), Poly(D,L-lactide) , Poly(D-lactide).

Acid Terminated


NHBP08 -DL 100-1A PDLLA 0/100 COOH 0.05-0.20 / 6-20
NHBP09 -DL 100-2A PDLLA 0/100 COOH 0.15-0.30 / 10-25
NHBP10 -DL 100-5A PDLLA 0/100 COOH 0.40-0.60 / 45-80
NHBP11 -DL 100-7A PDLLA 0/100 COOH 0.60-0.80 / 70-120

Ester Terminated

NHBP48 -DL 100-7E PDLLA 0/100 Ester 0.60-0.80 / 70-120
L-Lactide CAS 4511-42-6
D(+)-lactide – CAS 13076-17-0
DL-Lactide CAS 95-96-5
DL-Lactide CAS 95-96-5

Polyglycolic acid for sergical suture
PGA / Poly(2-hydroxyacetic acid) / 1.2 IV / Acid / 1Kg
End GroupEster - Ester Terminated, Acid - Acid Terminated, - Hydroxyl Terminated
*Not routinely stocked. Please call for a quote and availability.

*The price range for each 1gram of Polymer is $ 3.3 to 3.8 (USD)

Available variants​

01

Lactic acid isomers
L - Lactide
D - Lactide
DL - Lactide

02

Molecular Weight
10 kDa
to
120 kDa

03

End Group
Acid - Terminated
Ester - Terminated

04

Lactide & Glycolide (Compositions)
75:25   50:50
85:15   80:20
90:10   10:90

APPLICATION​

 

  • Poly(DL-lactide-co-glycolide) ester terminated; 50:50; IV 0.55-0.75 dL/g; Drug delivery (nanoparticles, in vitro, protein); particles were synthesized via a W/O/W emulsion technique;
    centrifugal fractioning used to control population distribution of particles.
  • Poly(DL-lactide-co-glycolide); MW 66 kDa; Drug delivery (nanoparticles, pDNA); Rat; prepared using a double emulsion solvent evaporation method; spinal cord injury; testing is done on the drug release, cytotoxicity, cellular uptake, and transfection.
  • Poly(DL-lactide-co-glycolide) acid terminated; 50:50; IV 0.15-0.25 dL/g; Drug delivery (nanoparticles, magnesium gluconate dihydrate); microspheres were fabricated by utilizing the double emulsion solvent evaporation technique with some modifications; "Cytotoxicity levels did not surpass the 15% cytotoxicity marker...which indicates sufficient biocompatibility"
  • Poly(DL-lactide-co-glycolide); 50:50; IV 0.76-0.94 dL/g; Drug delivery (nanoparticles, superoxide dismutase, catalase); rat (male Sprague-Dawley); double-emulsion solvent-evaporation method used for nanoparticle production; "delivery of nano-CAT/SOD at the time of reperfusion effectively protects neuronal cells"
  • Poly(DL-lactide-co-glycolide); 50:50; IV 0.26–0.54 dL/g; Drug delivery (nanoparticles, paclitaxel, NIR dye SDB5700); mice (male, athymic, nude); Nanoparticles were prepared by a single oil-in-water emulsion solvent evaporation method.
  • Poly(DL-lactide-co-glycolide) acid-terminated; 50:50; IV 0.26-0.54 dL/g; Drug delivery (nanoparticles, ceftiofur); Rat (Sprague-Dawley); Nanoparticles were prepared by double-emulsion method; sustained release profile of drug for 20 days.
  • Poly(DL-lactide-co-glycolide); 50:50; IV 0.15-0.25 dL/g; Drug delivery (nanoparticles, oxcarbazepine); prepared at room temperature (22°C-23°C) by a modified solvent displacement
    method; particle size, size distribution, and zeta potential measurements (in vitro); drug release profile
  • Poly(DL-lactide-co-glycolide) ester terminated; 50:50; IV 0.67 dL/g; Drug delivery (nanoparticles, nanosponge, a-toxin); mice; produced through nanoprecipitation in acetone.
  • Poly(DL-lactide-co-glycolide); 50:50; IV 0.55-0.75 dL/g; Drug delivery (nanoparticles, ovalbumin, Type 2 Herpes Simplex Virus glycoprotein D); C57BL/6 mice; Controlled delivery of stromal derived factor-1alpha from poly lactic-co-glycolic acid core-shell particles to recruit mesenchymal stem cells for cardiac regeneration.
  • Poly(DL-lactide-co-glycolide); 50:50; MW 31.3-57.6 kDa; Drug delivery (nanoparticles, stromal derived factor-1a); Coaxial electrospraying; sterilized using UV radiation.
  • Poly(L-lactide); MW 91-130 kDa; Drug delivery (nanoparticles, retinylamine); Mice (C57BL/6J); nanoparticles containing retinylamine were fabricated by a single emulsion technique; prevention of retinal degeneration.
  • Poly(DL-lactide-co-glycolide); 50:50; Drug delivery (nanoparticles, antigen); nanoparticles prepared using a double emulsion solvent evaporation method with modifications.
  • Poly(DL-lactide-co-glycolide) acid terminated; 50:50; IV 0.67 dL/g; Drug delivery (nanoparticles, docetaxel); rat (male, Sprague-Dawley); particles prepared in a nanoprecipitation process.
  • Poly(DL-lactide-co-glycolide); 50:50; Drug delivery (nanoparticles, bovine serum albumin); nanoparticles prepared by double emulsion solvent evaporation method with modifications.
  • Poly(DL-lactide-co-glycolide) ester terminated; 50:50; IV 0.55-0.75 dL/g; Drug delivery (nanoparticles, siRNA); nanoparticles were prepared using a modified water-in-oil-in-water double-emulsion solvent evaporation technique.
  • Poly(DL-lactide-co-glycolide) acid terminated; 50:50; IV 0.67 dL/g - MW 90 kDa; Drug delivery (nanoparticles, curcumin); formulated by solvent displacement method; IBR, cLABL peptides conjugated on the surface of PLGA nanoparticles using carbodiimide reaction; in vitro cytotoxicity testing